Investment Thesis
Dyne Therapeutics is a pre-revenue pharmaceutical company with severe operating losses (-$125.3M) and negative free cash flow (-$145.1M), indicating substantial development-stage burn with no commercial traction. While the balance sheet remains solid with $753.1M in cash providing 5+ years of runway, the absence of revenue generation capability and persistent negative returns on assets (-11.2% ROA) present fundamental profitability challenges.
Strengths
- Exceptional liquidity with 19.92x current ratio and $753.1M cash reserves
- Low leverage with 0.17x debt-to-equity ratio and minimal debt burden
- Extended cash runway of 5+ years at current burn rate supports continued operations
Risks
- Zero revenue with no commercial product generating sales
- Significant annual cash burn of -$145.1M with negative operating cash flow
- Persistent unprofitability with -$120.9M net loss and negative ROE/ROA metrics
- Long-term sustainability dependent on pipeline success with no near-term profitability visibility
Key Metrics to Watch
- Cash burn rate and remaining runway duration
- Revenue generation milestones and product commercialization timeline
- Operating loss trajectory and path to breakeven
- Clinical pipeline advancement and regulatory progress
Financial Metrics
Revenue
N/A
Net Income
-120.9M
EPS (Diluted)
$-0.73
Free Cash Flow
-145.1M
Total Assets
1.1B
Cash
753.1M
Profitability Ratios
Gross Margin
N/A
Operating Margin
N/A
Net Margin
N/A
ROE
-14.0%
ROA
-11.2%
FCF Margin
N/A
Balance Sheet & Liquidity
Current Ratio
19.92x
Quick Ratio
19.92x
Debt/Equity
0.17x
Debt/Assets
19.9%
Interest Coverage
-41.79x
Long-term Debt
149.4M
Disclaimer: This analysis is generated by AI based on publicly available SEC EDGAR filings.
It does not include stock price data and should not be considered financial advice.
All fundamental data is sourced from SEC public domain filings.
Always conduct your own research before making investment decisions.
Data Source: SEC EDGAR |
Analysis Date: 2026-05-16T09:03:54.822684 |
Data as of: 2026-03-31 |
Powered by Claude AI